President Donald Trump promised a $100 million investment in pharmaceutical manufacturing in Kentucky on Saturday but appeared to condition the funding on Republicans winning November's midterm elections. Kentucky Republicans expected at the event included Republican Senate candidate Andy Barr and 4th Congressional District candidate Ed Gallrein. Gallrein defeated incumbent Republican Representative Thomas Massie in this year's GOP primary after receiving Trump's backing.
The president's wording appeared to explicitly tie the $100 million investment to the outcome of the midterms. Details about how the proposed investment would be structured, when it would be made, and the precise status of the Winchester facility were not immediately clear. Newsweek has reached out to Antheia for comment and further details about the proposed investment.
The announcement came as Trump made manufacturing and the economy central themes of his speech. He predicted economic improvements as new plants come online. Antheia, a California-based pharmaceutical ingredient manufacturer, produces key starting materials, or KSMs, and active pharmaceutical ingredients, or APIs, used in essential medicines.
The company says its biosynthesis technology offers an alternative to pharmaceutical supply chains dependent on agricultural sources, which can be vulnerable to poor yields and other disruptions. The company's first commercial product is thebaine, a starting material used to manufacture medication for severe and postsurgical pain, overdose reversal, and addiction treatment. Antheia announced its first commercial delivery of thebaine in 2024 and has also been developing ingredients including oripavine and scopolamine.
Trump's announcement comes amid a broader federal push to increase domestic production of critical pharmaceutical ingredients. In March, the Department of Health and Human Services' (HHS) Administration for Strategic Preparedness and Response announced a $9 million award to Antheia to expand domestic production of thebaine. The agency said the ingredient is used to manufacture medicines for pain management, alcohol use disorder, and opioid overdose reversal, while citing reliance on foreign supply chains as a potential vulnerability.
Antheia had previously received another government-backed project agreement valued at up to $12 million through a program funded by HHS' Defense Production Act Title III program. The $100 million figure Trump announced Saturday would therefore be considerably larger than either of those previously announced federal commitments, although details about the proposed Winchester project and what would be manufactured there have not yet been established publicly. Trump also addressed the ongoing conflict with Iran during Saturday's rally, saying: “It's going to end very quickly.” At another point, he called the U.S. action against Iran an “excursion,” saying: “When I did the little excursion to the beautiful Islamic Republic of Iran, we beat the s*** out of 'em.” The rally was briefly interrupted by a protester who was removed by security.
Extract — continue reading at the source.
